Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with a poor prognosis. To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986 and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004.
INTRODUCTION
Mantle cell lymphoma (MCL) is a disease predominantly found in the elderly male population, associated with rapid progression, only temporary responses to chemotherapy, and a high recurrence rate, resulting in a poor long-term prognosis with reported median survival time of only approximately 3 to 4 years. [1] [2] [3] [4] With an incidence of about 0.4 per 100,000 per year, MCL is a relatively rare entity and accounts for roughly 7% of all lymphoma subtypes. 5, 6 In the majority of patients, the disease presents with advanced Ann Arbor stages III and IV which are regarded as incurable with conventional therapy. Whereas in 1970s treatment options mostly comprised chlorambucil and prednisone 7 and cyclophosphamide, vincristine, and prednisone (COP), 8 more aggressive approaches like cyclophosphamide, vincristine, prednisone, and doxorubicin (CHOP), or even hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate-cytarabine, 9 are nowadays applied mostly supplemented by the anti-CD20 antibody rituximab. 10, 11, 12 In remission, myeloablative radiochemotherapy with autologous stem-cell transplantation or other dose-intensified approaches are commonly applied in younger patients.
9,13-19 However, in contrast to follicular lymphoma, an improvement of overall survival has not yet been described in MCL patients. 20 In order to detect potential changes in the outcome of patients with advanced stage nonblastoid MCL within the past 30 years, a historical comparison was performed based on data from the Kiel Lymphoma Study Group (KLSG), collected from 1975 to 1986, and the data set from the German Low Grade Lymphoma Study Group (GLSG), recorded since 1996. Frequency matching as well as a multiple regression analysis was applied to adjust potential imbalances in the risk profile of the two patient populations.
PATIENTS AND METHODS

Study Population
The KLSG study population included patients of a prospective observational study 1 and a randomized controlled trial, 21 initiated in 1975 and 1982, respectively. The KLSG observational study followed 1,127 newly diagnosed and previously untreated patients with non-Hodgkin's lymphoma including 76 patients with advanced centrocytic lymphoma (WHO classification: MCL). 1, 22 The randomized KLSG trial compared the COP regime with the anthracycline-containing CHOP scheme in 74 patients with advanced MCL (Table 1) . 21 Every histology was diagnosed centrally by Karl Lennert, MD, German Lymph Node Registry at the Institute of Pathology, University of Kiel. Pathology review was performed by Henry Rappaport, MD, at the time of the studies. Diagnosis in the KLSG cohort was based on histomorphologic criteria only.
The GLSG study population included patients of two consecutive randomized trials with almost identical inclusion criteria, statistical evaluation methods, and study design. Previously untreated patients with advanced Ann Arbor stages III and IV MCL, follicular lymphoma, and lymphoplasmacytic lymphoma were included ( Table 1 ). The first trial was initiated in 1996 and investigated the efficacy of the CHOP regime compared with the mitoxantrone, chlorambucil, and prednisone (MCP) scheme 23 in 86 MCL patients. The second GLSG trial, initiated in 2000 explored the efficacy of the anti-CD20 antibody rituximab in combination with the CHOP regime versus CHOP alone in 122 MCL patients.
14 In both trials, after the planned end of random assignment, recruitment was continued assigning patients to the respective All patients with confirmed MCL (WHO classification) or centrocytic lymphoma (Kiel classification) with advanced Ann Arbor stage III or IV were included in this analysis, whereas patients with blastoid variants were excluded to guarantee a homogeneous study population.
Statistical Analysis
The primary end point of this study was the overall survival of patients with advanced stage MCL in the recent GLSG study population in comparison to the historical KLSG control group.
To obtain patients collectives with a comparable risk profile, the two patient collectives were divided into four risk groups by retrospective application of the risk factors of the International Prognostic Index (IPI) 24 (age, lactate dehydrogenase [LDH], Eastern Cooperative Oncology Group performance status, or Karnofsky index). In detail, the risk groups were determined No  32  9  16  8  18  12  16  12  Yes  322  91  176  92  132  88  118  88  Not available  6  10  0  0  Bone marrow  No  81  22  45  23  51  34  45  34  Yes  286  78  155  78  98  66  88  66  Not available  3  2  1  1  Spleen  No  160  48  89  49  56  40  52  40  Yes  176  52  94  51  87  60  77  60  Not available  34  19  5  5 by age (Ͻ 65 years, Ն 65 years) and by the absence or presence of at least one of the two remaining risk factors, elevated LDH or performance status of 2 to 4. The cutoff of 65 years was chosen as this age limit defines different therapeutic strategies (specifically myeloablative strategies). 14 The number of extranodal involvement was not included into the analysis, since information was lacking in part of the patients. The risk groups were then stratified according to sex, resulting in eight stratification groups.
For each of the eight stratification groups of the KLSG patient cohort, consecutive patients from the GLSG cohort belonging to the same stratification group were selected in ascending order of registration until reaching the highest possible matching ratio in all stratification groups (frequency matching). Because the GLSG cohort included more patients and in order to discard as little data as necessary, only patients of the GLSG cohort were excluded to adjust the risk profile to the KLSG cohort.
Overall survival was defined as the time from study inclusion until death. Study inclusion was immediately after diagnosis in KLSG and GLSG studies. If no event was observed, the survival time was censored at the date of last follow-up. Survival curves were estimated using the Kaplan-Meier method and compared by the log-rank test. In addition, the overall survival analysis was adjusted using the Cox proportional hazards model. In this multivariable analysis the following potential confounders were included: sex, age, serum LDH, performance status, Ann Arbor stage, bone marrow involvement, and B symptoms. All nonsignificant variables were excluded by backward selection on the basis of the Wald test statistic and possible interactions between the remaining influencing factors were also analyzed. In the final resulting model the adjusted effects of all variables were estimated. The significance level for all statistical analyses was set to ␣ ϭ .05.
RESULTS
Patient Characteristics and Potential Risk Factors
Three hundred seventy patients with classical MCL, according to the WHO classification in the GLSG collective (17% stage III and 83% stage IV) and 150 KLSG patients (30% stage III, 70% stage IV) were included in the analysis. As expected there was a 3:1 male predominance in both subgroups. However, a slightly different age distribution was observed in both study groups. The median age of the GLSG patients was 60 years (men) and 63 years (women) compared with 63 and 62 years in the KLSG collective, respectively (Table 2) . Accordingly, the proportion of patients older than 65 years in the GLSG cohort was 34% as compared with 46% in the KLSG cohort. A poor performance status (Eastern Cooperative Oncology Group performance status Ͼ 1) and the occurrence of B symptoms, like night sweats, fever, and weight loss, was observed slightly less frequently in the GLSG group (8% v 11% and 37% v 45%, respectively), whereas extranodal involvement and increased serum LDH occurred more often in GLSG patients (91% v 88% and 31% v 27%).
Therapy
In the KLSG studies, patients with MCL were treated mostly with either chlorambucil/prednisone (19%) or COP (39%), only 15% of the patients received the more intensive, anthracycline-containing CHOP therapy, whereas 9% were not treated at all. In contrast, in the GLSG protocols all patients were treated with MCP (13%), CHOP (52%), or rituximab plus CHOP (34%). After response to the initial therapy, 114 GLSG patients received interferon maintenance and 25 patients were subject to high-dose chemotherapy followed by autologous stem-cell transplantation.
Frequency Matching Procedure
Ten patients of the GLSG and 16 of the KLSG cohort were excluded due to missing frequency matching parameters. Of the 360 remaining GLSG patients, 202 were matched to the 134 remaining KLSG patients. A matching ratio of 2:3 for KLSG versus GLSG patients could be achieved (Tables 2 and 3; Fig 1) . The matching procedure resulted in an increase of median age from 61 to 64 years and a higher proportion of patients older than 65 years in the GLSG cohort (from 34% to 46% as in the KLSG cohort). Similarly, the proportion of patients with a poor performance status (ECOG Ͼ 1) rose from 8% to 10% in comparison to 11% in the KLSG cohort. Other baseline characteristics and potential risk factors were less affected (Table 2). 
Analysis of Overall Survival: Log-Rank Test
Within the observation period, death of 89 patients (44%) in the GLSG group and 88 (66%) in the KLSG group was documented. The comparison of the estimated survival curves shows a more favorable outcome in the risk-matched GLSG cohort (median overall survival, 4.8 years v 2.7 years in the KLSG group). Two years after study inclusion, 81% of the GLSG (95% CI, 76% to 87%) and 64% of the KLSG patients (95% CI, 55% to 72%) were still alive. After 5 years, survival rates of 47% in the GLSG (95% CI, 38% to 55%) and only 22% in the KLSG cohort (95% CI, 13% to 31%) were observed. Accordingly, the log-rank test 26 detected a significantly superior median overall survival in the GLSG patients (P Ͻ .0001; Fig 2) . Similarly, the median survival of the total GLSG cohort was 4.8 in comparison to 2.6 years in the KLSG patients (P Ͻ .0001).
Follow-up as estimated using the inversed Kaplan-Meier estimator was comparable with median follow-up times of 5.0 years and 4.6 years for matched GLSG and KLSG cohorts.
Adjusted Analysis of Overall Survival: Cox Regression
The Cox proportional hazards model confirmed the survival difference of the two treatment periods and identified a poor performance status (ECOG Ͼ 1 or Karnofsky index Ͻ 70), an elevated serum LDH, and higher age as additional prognostic factors. Ann Arbor stage, bone marrow involvement, B symptoms, sex, and possible interactions did not show additional prognostic impact.
The proportional hazard assumption was verified graphically for all variables looking at the survival functions as well as the negative logarithmized survival functions and no violations of the proportional hazard assumptions were detected.
The relative mortality risk in the GLSG patients was 0.44 as compared with the KLSG patients after adjustment for the identified clinical risk factors (Table 4 ; P Ͻ .0001; unadjusted relative risk, 0.47). A poor performance status (ECOG Ͼ 1) more than doubled the risk of death as compared to patients with a good performance status (hazard ratio, 2.26). An elevated serum LDH and a 10-year increase of age caused a 75% and 38% increase in mortality risk, respectively.
Analysis of Overall Survival Differentiated by Individual Studies
Overall survival curves of the individual KLSG studies are shown in Figure 3 . Median overall survival was almost identical with 2.6 years in the observational study and 2.7 years in the randomized controlled trial.
In contrast, median overall survival was almost twice as high in the MCP versus CHOP study (4.8 years) and not yet reached in the CHOP versus CHOP ϩ AntiCD20 study (Fig 3A) . For the latter study, the 2-year survival was 81% after a median follow-up of 1.5 years. 
DISCUSSION
The historical comparison of patients with advanced nonblastoid MCL on the basis of studies of two different eras (KLSG, 1975 (KLSG, to 1986 GLSG, 1996 GLSG, to 2004 ) demonstrated that the overall survival significantly increased within the past 30 years from 2.7 years up to 4.8 years in the recent studies. The 5-year survival rates more than doubled from 22% to 47%. The high number of more than 500 patients from the four included studies allowed us to analyze frequency-matched patient subgroups with similar clinical risk profiles such as age, sex, stage of disease, serum LDH, and performance status. In addition, by adjusting the overall survival analysis by a multivariable Cox proportional hazards model, all available potential confounders were controlled. Overall survival is highly dependent on the risk profile of the analyzed patient cohort. Therefore, patient selection is a great caveat of historical comparisons. Similarly, different classification systems may hamper any comparison. The observation study of the KLSG was based on the Kiel classification whereas the GLSG studies applied the current WHO classification. However, centrocytic lymphoma according to the Kiel classification is accepted to be classified as nonblastoid MCL in the WHO classification. 22 In addition, every pathologic examination of the KLSG studies was retrospectively reviewed by two experienced hematopathologists at the time of diagnosis. In the GLSG studies, pathologic findings were centrally reevaluated by a pathology panel using well-defined criteria. 27 In addition, blastoid MCL variants were excluded to match the WHO term of (classical) MCL as much as possible to the Kiel term of centrocytic lymphoma. Thus, we believe that both patient collectives are highly comparable in regard to diagnosis. The addition of immunohistochemistry, especially the staining of cyclin D1 expression in the GLSG series, may have led to a refined histomorphologic diagnosis; thus, differential diagnosis to other lymphoma subtypes, especially CLL, might be stricter nowadays. However, this round cell variant represents only a small percentage of patients in our cohorts, with probably no major overall effect.
Despite matching procedure and adjusted analyses, differences in undetected risk factors between the matching groups due to different inclusion criteria cannot be completely excluded. Whereas the KLSG studies included all newly diagnosed, previously untreated patients with centrocytic lymphoma without any further exception, the GLSG studies exclude patients with serious accompanying diseases. Thus, a slightly more favorable prognosis may be expected for the GLSG collective.
In addition, in the early KLSG observational study, MCL was considered to be indolent and observed until symptoms occurred. Hence, some patients were not treated upfront in contrast to the KLSG randomized controlled trial. However, both of the KLSG studies displayed an almost identical survival curve in the KLSG collective.
Another potential bias could be the date of study inclusion. The KLSG studies applied the date of first diagnosis whereas in the GLSG studies start of observation was defined as the date of registration. However, registration to GLSG trials was immediately after diagnosis, since MCL patients were considered in need of therapy at the time of diagnosis. Accordingly, the median delay between first diagnosis and registration in the GLSG cohort was 27 days, which therefore may result in a slight underestimation of the overall survival in the GLSG collective. In contrast, as the overall survival is determined unambiguously by the date of death, differences in the quality of data collection and documentation may be neglected.
What are the reasons for the remarkable prolongation of the overall survival? The superior outcome may be a result of different patient selection, improved diagnosis, the improved cytostatic therapy, or improved general supportive therapy. MCL is now treated earlier, more aggressively, and more vigorously than during the KLSG observation study when it was still regarded as indolent disease. Assessing the poor response to chlorambucil and the COP regime, the superiority of the anthracycline-containing CHOP regime may be one potential reason. However, the KLSG randomized trial failed to reveal a significant advantage CHOP as compared with COP. In contrast, in a retrospective study, Zucca et al 1995 3 found a longer overall survival in patients with a low or intermediate risk according to the IPI. A similar overall survival of 41.2 months was described in another retrospective study, 28 in which patients were also treated with an anthracycline-containing protocol. After completion of the two KLSG studies, promising approaches like myeloablative chemotherapy followed by autologous stem-cell transplantation as well as the anti-CD20-antibody rituximab were added to conventional chemotherapy.
14,15 Furthermore, general medical care has improved during the past 30 years resulting in reduced infection rates and other chemotherapeutic adverse effects which may lead to better compliance.
Improvements were not only made in treatment, but also in more sensitive staging techniques, like computed tomography and other imaging procedures. Indeed, during the time of the KLSG studies, extranodal involvement was not easily detectable. Therefore, a shift of staging accuracy cannot be excluded.
Another point which has to be taken into consideration is the improved survival expectancy in the general population in the past 30 years. Thus, the average life span of 65-year-old people increased by 2.7 years for men (from 12.4 to 15.1 years) and 3.0 years for women (from 15.9 to 18.9 years). 29 However, in other malignant diseases with a similarly aggressive clinical course such as lung cancer, no such improvement of overall survival has been detected. Therefore, prolonged median overall survival in advanced MCL and the doubling of 5-year survival rates is likely to indicate the major improvement of therapy in the past 30 years, even though MCL is still regarded as incurable.
We conclude that median overall survival of advanced-stage nonblastoid MCL patients increased by almost twofold within the past three decades, even though MCL therapy is still noncurative. Improved diagnostic methods, progress in therapeutical options, including the application of anthracycline-containing regimens, and the development of new approaches, like antibody therapy or stem cell transplantation, probably play an important role as well as improvement of supportive care. However, our results are questioning the validity of historical comparisons which had been frequently applied in previous trials to confirm the superiority of new therapeutic approaches.
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